

March 06, 2018

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Intimation for Investor Presentation

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the investor presentation. This investor presentation shall be made available to the analysts and fund managers of mutual funds during New India Conclave 2018 which shall going to be held on March 07, 2018 at Trident Hotel, BKC, Mumbai.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**



Ashvin Variya
Company Secretary & Compliance Officer
Place: Surat



Encl: a/a

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Zota Health Care Limited Investor Presentation

March, 2017

 **davaindia™**
GENERIC PHARMACY

dava vahi, daam sahi



Company Overview

Zota group is the fastest growing Indian Pharmaceutical group with a portfolio comprising wide range of Pharmaceutical, Nutraceutical as well as Ayurvedic products since 1995.

Zota group is wholly developed and managed by Zota and its family. The business began with a single pharmaceutical outlet in Surat, Gujarat. The group entered in the Indian pharmaceutical market with a unique business model called Franchisee Brand Marketing in pharma formulations. Today, Zota has 1000 direct distributors for its franchisee marketing on PAN India basis. Zota has a total of 3000 brand products.

Franchisee Brand marketing: In franchisee marketing business model Zota outsource manufactured products from top manufacturers of India. The random quality checks of products are done by its own scientists, 1 Sr. Scientist and 3 Scientist. Zota deal's with 30-35 manufacturer all over India; where, Akums Pharma, Theon Pharma, Synochem, Curetech Skin Care etc. are major Pharma manufacturer in India.

Zota manufacture's its product with MRP, with margin for self and for its distributors. Then they provide offer to franchisee on cash basis with zero liability.

Zota Healthcare Ltd. has three verticals of pharmaceutical [Franchisee business model]

- Domestic
- Export
- Retail Pharmacy Chain - Generic (Newly initiated, since October 2017)

Domestic vertical

100% outsource business. Zota has 1000 direct distributors for franchisee marketing and also adds 30-40 distributors on YoY basis. Gross Margin = 30% -40%, EBITDA Margin = 15%-17%. For FY17, 90% of total revenue generated from domestic business i.e. Rs. 66 crs. out of Rs. 70 crs.

In domestic market the company has its minimum target of sales of INR 3 lakhs p.a. from per distributor for per district. Zota has wide range of 3000 products under different names and network of sales through 21 marketing division with strong supply chain. Top 10 distributors contribute only 15% of total revenue and are mainly from Patna, Gorakhpur, Orrisa, Rajasthan, Kerala and Guwahati. Approximately 1-2 lakh doctors reach in Indian market are through distributors.

Zota having 6 unique product patent approvals & 12 more under consideration at India Patent Office. Top selling molecule is one patent product specifically for liver (RTFit, GMFit).

Major revenues are generated from Antibiotic products i.e. 15% - 20%, balance revenue are scattered in other products are, Cardiac, Diabetic, Nutraceuticals, Liquid, Injection, Eye-drop, Ointments Derma Products, Dental Range, Nutraceuticals etc. Zota is the leading company in India operating the franchisee business model. There are few players like Intra Lab, Zee Lab and are non-listed but; no major competitor on Pan India basis.

Export vertical

Company has its plant at Surat SEZ, in 2011 - Plant cost 9 crs, registration cost 2 crs. Total Plant capacity to cater 60-70 Crs Revenues, Management estimates - Gross margin = 55%, EBITDA margin = 30% In export vertical Zota will follow same business model i.e. franchisee for foreign market.

Zota Health Care Limited Investor Presentation

March, 2017

 **davaindia™**
GENERIC PHARMACY

dava vahi, daam sahi



Export targeted in 18 countries from Africa, Asia, Latin America and CIS region with 215 total product approvals. Rs 3 crs - Rs 3.5 crs orders in hand. For majority countries plant approval has been done, Zota currently applied for registration and also expecting to receive all approvals within 6 months period. These approvals will impact topline from export contribution, drastically.
FY17 = Rs 4.93 crs, 1HFY18 = Rs 5.23 crs

Davaindia Generic Pharmacy Purely Generic Retail Chain

In October 2017, company entered in generics market with Davaindia Generic Pharmacy Retail Chain, with same franchisee business model. Zota started with 4 generics, Davaindia Generic Pharmacy - 3 in Surat and 1 in Navsari. The franchisee at Navsari & Surat already started business of Rs.12000-20000.

Company has 900 molecules at present and targeting to reach around 1500 molecules in next 6 months. In Indian Generic Market Average 400 to 500 molecules are available.

Zota healthcare targeted to run 3000 Davaindia Generic Pharmacy in next 4 years all over India and to open 350 stores by FY19. At present company is planning to cover Tier-I, Tier-II and Tier-III cities. Company engaged in to setting up Davaindia Generic Store in states of Madhya Pradesh, Maharashtra and Gujarat, focusing on Mumbai to begin with. Company's short term target is to start 150 stores in next 6 months.

In Generic vertical company will concentrate on therapy medicines of which large part will be of all Chronic like Cardiac, Diabetic, Thyroid, Neuro-psychiatrist as well. In generic business 60% portion consist medicines and 40% portion consist of Cosmetics, OTC, Nutraceuticals, Ayurvedic etc., mainly to build the trust amongst buyers.

Investment Rationale

- Earnings = EBITDA, as no major expenses in-between. Debt - till date Zero debt company, Surplus Rs.25 crs.
- Capex - Zero Capex as it is a franchisee business all cost will be taken care by distributor himself. The overall spending incurred by company will be for inventory.
- Promotions and advt. expenses - till date no major promotion expenses incurred. Going forward management will invest in this expenses majorly for Davaindia Generics Business. All promotional ideas and mediums are ready to be executed in the form of Print Media, Radio, TV and social media.

Risks

Government policy change (loan License)

(Management is confident that this risk will not be practically implementable and in under any circumstances if it is proposed then the scenario will not change immediately as there will be product shortage in Indian market.)

Government has problems for procurement in Generics business, they have only 100 molecules available at present and there is no planned/ strong supply chain management as well.)

Game Changer

Davaindia is Game Changer. Government helps to promote Generic. If Government policy are made compulsorily to doctor for Generic Prescription then it will be a game changer for company.

Zota Health Care Limited Investor Presentation

March, 2017

 **davaindia™**
GENERIC PHARMACY

dava vahi, daam sahi



ZOTA HEALTHCARE TO THRIVE ON INDIAN GENERIC MARKET, ROLLS OUT RETAIL OUTLETS

Zota Healthcare is gearing up to cash in on the US\$15 Bn Indian generic market which is growing at a CAGR of 16% and is expected to touch US\$ 30 Bn by 2020.

Towards this end, its business vertical Davaindia Generic Retail Stores has rolled out 4 Retail Stores and plans are afoot to close FY18 with as many as 50-odd stores. The Retail outlets will be spread over in Gujarat, Maharashtra, and M.P. A beginning has been made by opening 3 Retail outlets in its home town Surat and 1 in Navsari.

"We provide generic alternatives to branded medicines at approximately 1/3rd of the cost without compromising on the quality of the product or packaging," Mr. Himanshu Zota, Director, Zota Healthcare, said. The generic drugs are considered safe due to the testing process used by the Food and Drug Administration (FDA) and Zota maintains strict quality control standards, in compliance with WHO international guidelines.

Zota Healthcare has also launch its portal www.davaindia.com. On entering the drug type in the search option of the portal, the generic alternatives will be presented. Interestingly, the entire list of medicines available for a specific drug type will be generated along with the Name of the medicine, the manufacturing company and its price. In fact if a person decides to buy Zota's Davaindia medicines, he can easily locate a nearby store by entering the area pin code.

According to a joint study by the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and RNCOS, Generics would account for 85% share in domestic market by 2020 which is essentially fueled by cheap labor, patent cliff of blockbuster drugs and prevalence of lifestyle disease.

Till recently the consumption of generics in the domestic market had its own limitations owing to the influence of physicians in terms of prescribing branded medicines and lack of drug pricing control laws. However, the generics market is now looking up owing to some of the key initiatives announced by Modi Government to include price control policies and revision of Jan Aushadhi campaign.

Among these Retail Outlets, Zota Healthcare plans to stock its own stock

Financial Position (Rs. In Lakhs)	2012-13	2013-14	2014-15	2015-16	2016-17	1HFY18
Share Capital	1,196.95	1,196.95	1,436.34	1,436.34	1,436.34	1,754.34
Reserves & Surplus	212.02	384.18	395.66	707.85	839.66	4,897.02
Non-Current Liabilities (Includes Long term Borrowings)	452.36	418.75	246.25	272.69	257.54	8.82
Current Liabilities	1,207.69	1,484.26	1,960.12	1,988.27	2801.56	1,832.52
Non-Current Assets (Includes Fixed Assets)	936.91	926.34	842.40	855.64	932.54	3,106.24
Current Assets	2,132.11	2,557.79	3,195.96	3,549.51	4,447.94	5,386.46

Zota Health Care Limited Investor Presentation



March, 2017

davaindia™
GENERIC PHARMACY

dava vahi, daam sahi



Profit & Loss Statement (Rs. In Lakhs)	2012-13	2013-14	2014-15	2015-16	2016-17	1HFY18
Total Revenue	4,394.43	5,021.39	5,647.78	6,481.01	7,163.64	3,974.14
EBITDA	588.36	654.77	847.74	959.83	1,009.81	662.36
PBT	376.86	467.31	634.24	772.42	836.17	606.95
PAT	254.01	311.26	426.68	510.93	554.11	402.40



Zota Health Care Limited

Investor Presentation

March, 2017

 **davaindia™**
GENERIC PHARMACY

dava vahi, daam sahi



Contacts

Himanshu Zota

Whole Time Director

Email id: hzota@zotahealthcare.com

Ashvin Variya

Company Secretary & Compliance Officer

Email id: cszota@zotahealthcare.com

Disclaimer

This presentation has been prepared by the Zota Health Care Limited (the "Company") only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer documents. This presentation has been prepared on the basis of information and data available with the Company consider reliable. This presentation may not contain all the information that you may consider material. Any liability in respect of the content of or any omission from this presentation is expressly excluded.

Stakeholders are advice to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on website of NSE Emerge.

This presentation contains "forward looking statement", including "future oriented financial information" and "financial outlook". This forward looking statement is based on management's current expectations and belief, and subject to uncertainty. Actual result may be vary from the material facts contained in this presentation due to changes in government policies, regulations, economics reforms, natural calamities, competition, technology, etc. Company is not under obligation to inform any update or alter in forward looking statement, whether as a result of any new information or future events